<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2018.72026</article-id><article-id pub-id-type="publisher-id">TCM-24153</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20180200000_79791456.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  黄连素对肝癌Hep-G2细胞株的作用研究
  Effect and Mechanism of Berberine on Human Hepatocellular Carcinoma Cell Line Hep-G2
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>敏</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>志敏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>章</surname><given-names>必成</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>波</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>兰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>付</surname><given-names>红星</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>饶</surname><given-names>智国</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>解放军武汉总医院肿瘤科，湖北 武汉</addr-line></aff><aff id="aff1"><addr-line>湖北中医药大学2015级研究生班，湖北 武汉</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>15072356537@163.com(王敏)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>03</month><year>2018</year></pub-date><volume>07</volume><issue>02</issue><fpage>158</fpage><lpage>166</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨黄连素(berberine, BBR)作用于肝癌Hep-G2细胞增殖和凋亡的机制。方法：CCK-8法检测BBR对Hep-G2细胞增殖的抑制作用；流式细胞术检测BBR对细胞凋亡的影响；蛋白印迹法(Western blotting)及实时荧光定量PCR (RT-PCR)检测抗增殖基因BTG2及细胞周期蛋白CyclinB1、CyclinD1的蛋白及mRNA表达的情况。结果：与对照组相比，BBR可以抑制肝癌Hep-G2细胞的增殖，且抑制率与BBR浓度成正比，差异具有统计学意义(p &lt; 0.01)；与对照组相比，BBR可诱导细胞凋亡(p &lt; 0.01)，且凋亡率随着黄连素的作用时间的延长而增加(p &lt; 0.01)；BTG2 mRNA的表达随着BBR作用时间的延长逐渐增强(p &lt; 0.01)，且与对照组相比，差异具有显著性(p &lt; 0.01)，而CyclinB1、CyclinD1mRNA的表达则随着BBR作用时间的延长逐渐减弱(p &lt; 0.01或p &lt; 0.05)，与对照组相比，差异具有显著性(P &lt; 0.01)；与对照组相比，BTG2和CyclinB1、CyclinD1蛋白表达的差异具有显著性(p &lt; 0.05)。结论：BBR可抑制肝癌细胞Hep-G2的增殖，诱导细胞凋亡，其机制可能与其上调抗增殖基因BTG2和下调细胞周期蛋白CyclinB1、CyclinD1的表达有关。 Objective: To investigate the effect and mechanism of Berberine on inhibiting cell proliferation and inducing apoptosis in Hepatocellular carcinoma Hep-G2 cell line. Methods: The inhibitory ef-fect of Berberine on the proliferation of Hep-G2 cells was detected by CCK-8 method; effect of Berberine on cell apoptosis by flow cytometry (FCM); western blotting and real time fluorescent quantitative PCR (RT-PCR) analysis were used to detect the mRNA and protein expression of anti proliferation gene BTG2 and CyclinB1, cyclin D1. Results: The proliferation of Hep-G2 cell lines was inhibited by Berberine in a dose and time dependent manner, and compared with the control group, the difference was statistically significant (p &lt; 0.01). Berberine promotes cell apoptosis, and the rate of apoptosis is proportional to the effect time of Berberine (P &lt; 0.01). The expression of BTG2 mRNA increased with the time of Berberine treatment (p &lt; 0.01), and compared with the control group, there’s significant difference (p &lt; 0.01); while the expression of CyclinB1, CyclinD1 mRNA was gradually decreased with the time of Berberine intervention (p &lt; 0.01 or p &lt; 0.05), and the difference was significantly compared with the control group (p &lt; 0.01). Compared with the control group, the differential expression of BTG2 and CyclinB1, CyclinD1 protein was significant (p &lt; 0.05). Conclusions: Berberine can inhibit the proliferation of Hep-G2 cells and induce cells apoptosis, which mechanism may be related to the up-regulation of BTG2 and down-regulation of CyclinB1, Cyclin D1 by berberine. 
  
 
</p></abstract><kwd-group><kwd>黄连素，肝癌，细胞增殖，细胞凋亡，BTG2，细胞周期蛋白B1，细胞周期蛋白D1, Berberine</kwd><kwd> Hepatocellular Carcinoma</kwd><kwd> Cell Proliferation</kwd><kwd> Cell Apoptosis</kwd><kwd> BTG2</kwd><kwd> CyclinB1</kwd><kwd> Cyclin D1</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>黄连素对肝癌Hep-G2细胞株的作用研究<sup> </sup></title><p>王敏<sup>1</sup>，张志敏<sup>2</sup>，章必成<sup>2</sup>，杨波<sup>2</sup>，刘兰<sup>2</sup>，付红星<sup>2</sup>，饶智国<sup>2</sup></p><p><sup>1</sup>湖北中医药大学2015级研究生班，湖北 武汉</p><p><sup>2</sup>解放军武汉总医院肿瘤科，湖北 武汉</p><p>收稿日期：2018年3月6日；录用日期：2018年3月18日；发布日期：2018年3月26日</p><disp-formula id="hanspub.24153-formula143"><graphic xlink:href="//html.hanspub.org/file/9-2270291x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨黄连素(berberine, BBR)作用于肝癌Hep-G2细胞增殖和凋亡的机制。方法：CCK-8法检测BBR对Hep-G2细胞增殖的抑制作用；流式细胞术检测BBR对细胞凋亡的影响；蛋白印迹法(Western blotting)及实时荧光定量PCR (RT-PCR)检测抗增殖基因BTG2及细胞周期蛋白CyclinB1、CyclinD1的蛋白及mRNA表达的情况。结果：与对照组相比，BBR可以抑制肝癌Hep-G2细胞的增殖，且抑制率与BBR浓度成正比，差异具有统计学意义(p &lt; 0.01)；与对照组相比，BBR可诱导细胞凋亡(p &lt; 0.01)，且凋亡率随着黄连素的作用时间的延长而增加(p &lt; 0.01)；BTG2 mRNA的表达随着BBR作用时间的延长逐渐增强(p &lt; 0.01)，且与对照组相比，差异具有显著性(p &lt; 0.01)，而CyclinB1、CyclinD1mRNA的表达则随着BBR作用时间的延长逐渐减弱(p &lt; 0.01或p &lt; 0.05)，与对照组相比，差异具有显著性(P &lt; 0.01)；与对照组相比，BTG2和CyclinB1、CyclinD1蛋白表达的差异具有显著性(p &lt; 0.05)。结论：BBR可抑制肝癌细胞Hep-G2的增殖，诱导细胞凋亡，其机制可能与其上调抗增殖基因BTG2和下调细胞周期蛋白CyclinB1、CyclinD1的表达有关。</p><p>关键词 :黄连素，肝癌，细胞增殖，细胞凋亡，BTG2，细胞周期蛋白B1，细胞周期蛋白D1</p><disp-formula id="hanspub.24153-formula144"><graphic xlink:href="//html.hanspub.org/file/9-2270291x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-2270291x7_hanspub.png" /> <img src="//html.hanspub.org/file/9-2270291x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>原发性肝癌是我国常见的恶性肿瘤之一，肝细胞癌(hepatocellular carcinoma, HCC)占90%以上，最新资料显示HCC高居中国肿瘤发病的第3、4位和肿瘤死因的第2、3位 [<xref ref-type="bibr" rid="hanspub.24153-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref2">2</xref>] 。对于原发性肝癌的治疗，最根本的方法是手术切除，但由于起病隐袭、侵袭性高、进展迅速和早期诊断困难，我国HCC患者确诊时多己为局部晚期或者发生远处转移，往往不适合或不能够单独采取外科手术、肝动脉栓塞化疗(transcatheter arterial chemoembolization, TACE)或理化消融等局部治疗 [<xref ref-type="bibr" rid="hanspub.24153-ref3">3</xref>] 。这类患者预后很差。</p><p>黄连素又称小檗碱，1959年Hano [<xref ref-type="bibr" rid="hanspub.24153-ref4">4</xref>] 报道了其具有抗肿瘤活性。近年研究发现黄连素及其衍生物可选择性诱导人肝癌细胞死亡，但对人的正常肝细胞无细胞毒性，表明黄连素及其衍生物具有肝癌靶向细胞毒性，有可能成为有前途的多功能抗肝癌药物 [<xref ref-type="bibr" rid="hanspub.24153-ref5">5</xref>] 。本文以体外细胞实验研究黄连素调节抑癌基因BTG2和细胞周期蛋白CyclinB1、CyclinD1的表达来探讨其抗肝癌细胞株Hep-G2作用机制及可能影响的信号通路的研究，且该方面的研究及报道较少见，为其临床应用于肝癌的治疗提供理论基础，也为后期更为精确的用药提供理论支持。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 药品和试剂</title><p>黄连素(盐酸小檗碱)购自成都艾特姆生物科技有限公司；CCK-8试剂盒购自上海碧云天生物技术有限公司；PI染色试剂盒及AnnexinV-FITC/PI 凋亡检测试剂盒均购自Bio-Swamp公司；BCA蛋白浓度测定试剂盒购自上海碧云天生物技术有限公司，鼠抗BTG2和兔抗CyclinB1、CyclinD1抗体均购自Abcam公司；引物由上海Invitrogen生物制品公司合成；Trizol购自北京康为世纪生物科技有限公司，SYBR Green PCR试剂盒购自KAPA Biosystems公司，逆转录试剂盒购自TAKARA公司。</p></sec><sec id="s4_2"><title>2.2. 细胞系与细胞培养</title><p>人肝癌细胞株Hep-G2由中国典型培养物保藏中心(武汉大学保藏中心)提供，用MEM Hyclone培养基、10%胎牛血清、青霉素-链霉素溶液配制成的完全培养基，于37℃、5% CO<sub>2</sub>饱和湿度的细胞培养箱中培养，待细胞生长至对数生长期时备用。</p></sec><sec id="s4_3"><title>2.3. CCK-8检测BBR对Hep-G2细胞增殖的抑制作用</title><p>取对数生长期的Hep-G2细胞，接种于三个96孔板中，100 ul/孔，于37℃、5% CO<sub>2</sub>饱和湿度的细胞培养箱中培养24 h，待细胞贴壁后，给予不同浓度的BBR (12.5，25，50，100，200 &#181;mol/L)干预细胞，另设阴性对照组(只有细胞和培养基)和空白组(没有细胞只有培养基)，每个浓度设五个复孔，每个96孔板边缘孔均加入PBS 100 ul，分别培养24 h、48 h、72 h后，吸出原液，用遇冷的PBS洗涤一遍，每孔加入用MEM培养基稀释的CCK-8 100 ul，置于细胞培养箱中孵育三小时。用酶联免疫检测仪测定每孔在450 nm处的吸光度值，然后根据公式计算细胞增殖抑制率。实验重复三次。细胞增殖抑制率(%) = [1 − (实验组OD值 − 空白组OD值)/(阴性对照组OD值 − 空白组OD值)] &#215; 100%。经加权直线回归方程计算出黄连素抑制细胞增殖率为25%时的对应浓度值。</p></sec><sec id="s4_4"><title>2.4. 流式细胞术检测细胞周期变化及细胞凋亡率</title><p>取对数生长期的细胞，制成3 &#215; 10<sup>5</sup>/ml的单细胞悬液，接种于三个6孔板中，于37℃、5% CO<sub>2</sub>饱和湿度的细胞培养箱中培养24 h，待细胞贴壁后，给予抑制率为25%的BBR用药浓度对细胞进行处理，另设空白对照组，继续孵育24、48、72小时。孵育时间到后用遇冷的PBS洗涤两遍，胰酶消化，离心收集细胞，并重悬于200 ul的Binging Buffer中，再根据PI染色试剂盒和AnnexinV-FITC/PI凋亡检测试剂盒的说明书进行细胞染色，最后用流式细胞仪检测细胞周期及凋亡细胞分布情况。实验重复三次。</p></sec><sec id="s4_5"><title>2.5. Western Blot检测BTG2和CyclinB1、CyclinD1的蛋白表达情况</title><p>取对数生长期的细胞，制成3 &#215; 10<sup>5</sup>/ml的单细胞悬液，接种于三个6孔板中，于37℃、5% CO<sub>2</sub>饱和湿度的细胞培养箱中培养24 h，待细胞贴壁后，给予抑制率为25%的BBR用药浓度对细胞进行处理，另设空白对照组，继续孵育24、48、72小时。收集细胞后提取蛋白并根据BCA蛋白浓度测定试剂盒说明书测定各组蛋白的含量，每组样品各取40 &#181;g蛋白进行上样。根据10% SDS-PAGE凝胶试剂盒制成分离胶和5%的浓缩胶，进一步电泳、转膜，将凝胶上的蛋白转移至NC膜上。用5%的BSA室温下于摇床上封闭1小时，加入一抗(鼠抗BTG2和兔抗CyclinB1、CyclinD1，工作液的浓度分别为1:500、1:1000和1:1000)，于4℃冰箱里孵育过夜，1 &#215; TBST洗涤液洗膜后再加入相应的二抗((1:5000 HRP 标记的羊抗兔IgG和羊抗鼠IgG),室温下于摇床上孵育30 min，以β-actin作为内参。仍然用1 &#215; TBST洗涤液洗膜后，用ECL化学发光法进行观察。实验重复三次。</p></sec><sec id="s4_6"><title>2.6. RT-PCR检测BTG2和CyclinB1、CyclinD1 mRNA的表达</title><p>取对数生长期的细胞，制成3 &#215; 10<sup>5</sup>/ml的单细胞悬液，接种于三个6孔板中，于37℃、5% CO<sub>2</sub>饱和湿度的细胞培养箱中培养24 h，待细胞贴壁后，给予抑制率为25%的BBR用药浓度对细胞进行处理，另设空白对照组，继续孵育24、48、72小时。孵育时间到后收集各组细胞，提取蛋白后用Trizol提取总RNA，并测定RNA的质量，根据逆转录试剂盒说明书将总RNA逆转录成cDNA，根据该试剂盒的说明书，反转录的条件是：20 uL反应体系，其反应程序是42℃，60 min；70℃，10 min；−20℃，hold。根据PCR试剂盒说明书及荧光定量PCR仪对cDNA进行扩增，反应体系20 uL：PreMix 10 μL、上游引物0.5 μL、下游引物0.5 μL、cDNA 模板1 μL及ddH<sub>2</sub>O 8 μL，PCR扩增反应程序设置：94℃预变性1 min；94℃变性15 s，58℃退火20 s，72℃延伸20 s，循环40次；72终末延伸5 min；4℃保温。最后运用c-omparative2<sup>−</sup><sup>△△</sup><sup>CT</sup> 法分析各基因的相对表达。实验重复三次。所用引物序列见表1。</p></sec><sec id="s4_7"><title>2.7. 统计学处理</title><p>应用SPSS 20.0软件进行实验数据的统计学分析，实验数据均以<inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/9-2270291x9_hanspub.png" xlink:type="simple"/></inline-formula>表示，多组间比较采用单因素方差分析，组间两两比较采用LSD检验，若方差不齐则采用Tamhane检验，以p &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. BBR对肝癌Hep-G2细胞增殖的影响：见表2</title><p>各组BBR作用于HepG-2细胞12 h、24 h、48 h、72 h后，细胞生长出现明显抑制，且细胞生长抑制率随药物浓度的增加而升高。经加权直线回归方程计算出BBR作用于HepG-2细胞24 h的抑制率为25%的BBR用药浓度为30 &#181;mol/L。</p></sec><sec id="s5_2"><title>3.2. BBR对Hep-G2细胞凋亡的影响：见图1，表3</title><p>将浓度为30 &#181;mol/L的BBR干预Hep-G2细胞24 h、48 h、72 h小时后，与对照组相比，实验组细胞凋亡率增加，具有明显的时间依耐性，差异具有显著性(P &lt; 0.01)。</p></sec><sec id="s5_3"><title>3.3. BBR对Hep-G2细胞BTG2 mRNA和CyclinB1、CyclinD1mRNA表达的影响：见图2</title><p>将浓度为30 &#181;mol/L的BBR分别干预细胞24 h、48 h、72 h后，与对照组相比，BTG2 mRNA的相对表达量逐渐增加(P &lt; 0.01)，随着作用时间的延长增加更显著(P &lt; 0.01)。而CyclinB1、CyclinD1mRNA的表达，与对照组相比，逐渐减低(P &lt; 0.01)。</p></sec><sec id="s5_4"><title>3.4. BBR对Hep-G2细胞BTG2和CyclinB1、CyclinD1蛋白表达的影响：见图3</title><p>与对照组相比，将浓度为30 &#181;mol/L的BBR分别干预细胞24 h、48 h、72 h后，BTG2蛋白的表达逐渐增高(P &lt; 0.01)。同时CyclinB1、CyclinD1蛋白的表达逐渐减弱(P &lt; 0.01或P &lt; 0.05)。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>黄连素，可从传统中药黄连、黄柏、三颗针等植物中提取，黄连素及其衍生物在治疗心血管疾病、抗肿瘤、免疫调节、精神疾病、骨质疏松等多方面具有一定的药理作用。近年研究显示黄连素可通过诱导ROS生成 [<xref ref-type="bibr" rid="hanspub.24153-ref6">6</xref>] 、调节HIF-1α、抑癌因子p21WAFl/CIPl、细胞周期蛋白CyclinB1的表达 [<xref ref-type="bibr" rid="hanspub.24153-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref8">8</xref>] 、触发Caspase-3、Caspase-8和Caspase-7的活性 [<xref ref-type="bibr" rid="hanspub.24153-ref9">9</xref>] 、抑制NF-κB的活性及其通路影响VEGF mRNA和蛋白的表达 [<xref ref-type="bibr" rid="hanspub.24153-ref10">10</xref>] 、提高GRP78/HSPA5的表达 [<xref ref-type="bibr" rid="hanspub.24153-ref11">11</xref>] 等多种途径影响肿瘤细胞的增殖、调控细胞周期、抑制侵袭及转移、调节自噬、增敏增效等方面发挥其抗肿瘤作用。</p><p>BTG2 (B-cell translocation gene-2)作为一种抗增殖基因，是早期瞬时反应基因之一，属于BTG/Tob抑癌基因家族成员之一。已有大量研究证实，BTG2在许多肿瘤中的表达下调，在多种肿瘤细胞的分化、</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Real-time fluorescence quantitative PCR primers were used in this stud</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >基因</th><th align="center" valign="middle" >序列(5’-3’)</th><th align="center" valign="middle" >长度(bp)</th></tr></thead><tr><td align="center" valign="middle" >BTG2</td><td align="center" valign="middle" >正向：GCCAGCCAGATCGGACTC 反向：TCGTACAAGACGCAGATGGAG</td><td align="center" valign="middle" >128</td></tr><tr><td align="center" valign="middle" >Cyclin B1</td><td align="center" valign="middle" >正向：GGTCGGGAAGTCACTGGAAAC 反向：CAGCATCTTCTTGGGCACAC</td><td align="center" valign="middle" >153</td></tr><tr><td align="center" valign="middle" >Cyclin D1</td><td align="center" valign="middle" >正向：CAATGACCCCGCACGATTTC 反向：CATGGAGGGCGGATTGGAA</td><td align="center" valign="middle" >146</td></tr><tr><td align="center" valign="middle" >β-actin</td><td align="center" valign="middle" >正向：CTGGGCTACACTGAGCACC 反向：AAGTGGTCGTTGAGGGCAATG</td><td align="center" valign="middle" >218</td></tr></tbody></table></table-wrap><p>表1. 本研究使用的实时荧光定量PCR引物序列</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the growth inhibition rate of hepg2 cells with different concentrations of berberine at different time levels (%,</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >12 h</th><th align="center" valign="middle" >24 h</th><th align="center" valign="middle" >48 h</th><th align="center" valign="middle" >72 h</th></tr></thead><tr><td align="center" valign="middle" >空白对照组</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >12.5 μmol/L</td><td align="center" valign="middle" >7.76 &#177; 0.13<sup>a</sup></td><td align="center" valign="middle" >17.40 &#177; 0.10<sup>a</sup></td><td align="center" valign="middle" >18.97 &#177; 0.14<sup>a</sup></td><td align="center" valign="middle" >25.03 &#177; 0.23<sup>a</sup></td></tr><tr><td align="center" valign="middle" >25 μmol/L</td><td align="center" valign="middle" >14.95 &#177; 0.07<sup>ab</sup></td><td align="center" valign="middle" >22.97 &#177; 0.04<sup>ab</sup></td><td align="center" valign="middle" >26.82 &#177; 0.97<sup>ab</sup></td><td align="center" valign="middle" >37.16 &#177; 0.21<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >50 μmol/L</td><td align="center" valign="middle" >39.36 &#177; 0.09<sup>abc</sup></td><td align="center" valign="middle" >52.49 &#177; 0.04<sup>abc</sup></td><td align="center" valign="middle" >56.83 &#177; 0.16<sup>abc</sup></td><td align="center" valign="middle" >62.27 &#177; 0.13<sup>abc</sup></td></tr><tr><td align="center" valign="middle" >100 μmol/L</td><td align="center" valign="middle" >56.32 &#177; 0.06<sup>abcd</sup></td><td align="center" valign="middle" >62.46 &#177; 0.69<sup>abcd</sup></td><td align="center" valign="middle" >66.18 &#177; 0.15<sup>abcd</sup></td><td align="center" valign="middle" >71.90 &#177; 0.01<sup>abcd</sup></td></tr><tr><td align="center" valign="middle" >200 μmol/L</td><td align="center" valign="middle" >62.37 &#177; 0.77<sup>abcde</sup></td><td align="center" valign="middle" >70.25 &#177; 0.24<sup>abcde</sup></td><td align="center" valign="middle" >71.23 &#177; 0.14<sup>abcde</sup></td><td align="center" valign="middle" >74.32 &#177; 0.05<sup>abcde</sup></td></tr></tbody></table></table-wrap><p>表2. 不同浓度的BBR培养HepG2不同时间后细胞生长抑制率的比较(%，<inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/9-2270291x11_hanspub.png" xlink:type="simple"/></inline-formula>)</p><p>注：BBR为黄连素；Hep-G2为人肝癌细胞株；每组每个时间点的样本量为3；<sup>a</sup>代表与空白对照组的比较P &lt; 0.01；<sup>b</sup>代表与12.5 μmol/L的比较P &lt; 0.01；<sup>c</sup>代表与25 μmol/L的比较P &lt; 0.01；<sup>d</sup>与50 μmol/L的比较P &lt; 0.01；<sup>e</sup>与100 μmol/L的比较P &lt; 0.01。</p><p>图1. 流氏细胞仪测BBR对Hep-G2细胞凋亡的影响</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The comparison of the apoptosis rate of Hep-G2 cells with a certain concentrations of berberine at different time levels (%,</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >凋亡期</th><th align="center" valign="middle" >24 h</th><th align="center" valign="middle" >48 h</th><th align="center" valign="middle" >72 h</th></tr></thead><tr><td align="center" valign="middle" >对照组 实验组</td><td align="center" valign="middle" >早期</td><td align="center" valign="middle" >0.05 &#177; 0.09 3.72 &#177; 0.17<sup>a</sup></td><td align="center" valign="middle" >2.20 &#177; 0.32 6.58 &#177; 0.39<sup>ab</sup></td><td align="center" valign="middle" >0.84 &#177; 0.15 10.70 &#177; 1.20<sup>abc</sup></td></tr><tr><td align="center" valign="middle" >对照组 实验组</td><td align="center" valign="middle" >中晚期</td><td align="center" valign="middle" >0 3.13 &#177; 0.24<sup>a</sup></td><td align="center" valign="middle" >2.16 &#177; 0.24 5.59 &#177; 0.28<sup>ab</sup></td><td align="center" valign="middle" >0.69 &#177; 0.27 14.82 &#177; 1.43<sup>abc</sup></td></tr></tbody></table></table-wrap><p>表3. 一定浓度的BBR培养Hep-G2不同时间后细胞凋亡率的比较(%，<inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/9-2270291x14_hanspub.png" xlink:type="simple"/></inline-formula>)</p><p>注：BBR为黄连素；Hep-G2为人肝癌细胞株；<sup>a</sup>代表与对照组相比P &lt; 0.01；<sup>b</sup>代表实验组之间与24 h的比较P &lt; 0.01；<sup>c</sup>代表实验组之间与48 h的比较P &lt; 0.01。</p><p>图2. BBR对Hep-G2细胞BTG2和CyclinB1、CyclinD1mRNA表达的影响</p><p>图3. BBR对Hep-G2细胞BTG2和CyclinB1、CyclinD1蛋白表达的影响</p><p>增殖、DNA损伤修复以及凋亡中起重要作用 [<xref ref-type="bibr" rid="hanspub.24153-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref16">16</xref>] ，且与肿瘤的大小、分级、转移、复发及预后不良都有一定关系 [<xref ref-type="bibr" rid="hanspub.24153-ref17">17</xref>] 。多个实验研究表明上调BTG2的表达，可抑制乳腺癌、前列腺癌、胶质母细胞瘤等肿瘤细胞的增殖、诱导细胞凋亡 [<xref ref-type="bibr" rid="hanspub.24153-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref21">21</xref>] 。目前，也有学者证实BTG2在肝癌组织中不表达或者表达非常低，而相应的癌旁组织或正常肝细胞中表达则较高，提示BTG2的高表达对肝癌的发生、进展均具有抑制作用 [<xref ref-type="bibr" rid="hanspub.24153-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref23">23</xref>] 。本实验结果发现一定剂量的黄连素干预Hep-G2细胞后，BTG2蛋白及mRNA的表达都随着时间延长逐渐增强，差异具有统计学意义。</p><p>细胞周期蛋白Cyclin B1作为Cyclins家族的一员，活化并与CDKs即CDC2 (cell division cycle)形成复合物，促使细胞进行G2/M期转变。有多项研究表明，Cyclin B1的表达，在肿瘤细胞的增殖中起重要作用 [<xref ref-type="bibr" rid="hanspub.24153-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref25">25</xref>] 。有研究 [<xref ref-type="bibr" rid="hanspub.24153-ref26">26</xref>] 发现人肝癌组织中CyclinB1 mRNA表达水平与临床分期、门静脉癌栓、术后复发、肿瘤直径和肿瘤低分化等成正相关。在本实验中当一定剂量的黄连素干预HepG-2细胞后，CyclinB1 mRNA和蛋白的表达均随着时间延长逐渐增强，具有明显时间依赖性，差异具有统计学意义。</p><p>Cyclin D1作为一种潜在的原癌基因蛋白，且是调控G1期的关键蛋白，并且在多种肿瘤中过表达。有研究表明下调Cyclin D1的表达，可使细胞周期阻滞在G1期，从而抑制肿瘤细胞增殖、诱导细胞凋亡 [<xref ref-type="bibr" rid="hanspub.24153-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref28">28</xref>] 。目前，另有学者研究cyclin D1在丙型肝炎相关性肝细胞肝癌组织中的表达较癌旁组织，以及基本正常肝脏组织明显增高，且与肝癌组织的病理学分级及患者的不良预后呈正相关，提示cyclin D1高表达的致癌作用 [<xref ref-type="bibr" rid="hanspub.24153-ref29">29</xref>] 。在本实验中当一定浓度的黄连素干预HepG-2细胞后，CyclinD1 mRNA和蛋白的表达均随着时间延长逐渐增强，具有明显的时间依耐性，差异具有统计学意义。</p><p>肿瘤发生的本质原因是癌基因的激活和(或)抑癌基因的失活。BTG2作为抗增殖蛋白基因，是细胞周期动力学的重要调节因子，与细胞周期的控制和细胞对DNA损伤反应有关。研究 [<xref ref-type="bibr" rid="hanspub.24153-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.24153-ref28">28</xref>] 发现提高BTG2的表达可抑制CyclinD1蛋白的转录活性，降低CyclinD1蛋白表达，然后通过经视网膜母细胞瘤基因(Rb)途径使细胞阻滞在G1期，促使细胞凋亡。BTG2也可通非Rb途径阻止CyclinB1和Cdc2的结合，抑制Cdc2激酶活性，导致G2期的停滞，而诱导G2/M期的细胞周期阻滞及细胞凋亡。在该实验中我们发现随着一定剂量的黄连素作用时间的延长，细胞的凋亡率逐渐增多，且BTG2蛋白表达逐渐上升，同时CyclinB1、Cyclin D1 mRNA及蛋白表达逐渐下调，引起细胞周期阻滞，诱导细胞凋亡。</p><p>由此我们推断，黄连素具有抑制肝癌细胞增殖，诱导细胞凋亡的作用。这与前期，我们实验组研究的48 h的半数抑制浓度IC50 = 41.18 μmol/L的黄连素调节肝癌HepG2细胞增殖和凋亡的结果相一致。其机制之一可能是通过上调抑癌基因BTG2的表达，同时引起CyclinB1、Cyclin D1的表达下调。但是在该实验中黄连素对抗增殖基因BTG2的作用机制并不清楚，有待进一步研究，且BTG2抗肿瘤的作用与Cyclin B1、Cyclin D1的表达抑制是否有直接相关性，也需要进一步实验来证实。若将黄连素用于肝癌的临床治疗，是否具有临床疗效，还需要临床试验及进一步深入探讨。</p></sec><sec id="s7"><title>基金项目</title><p>国家自然科学基金青年项目(81301631)。</p><p>湖北省卫计委青年人才项目(WJ2017H0036)。</p></sec><sec id="s8"><title>文章引用</title><p>王敏,张志敏,章必成,杨 波,刘 兰,付红星,饶智国. 黄连素对肝癌Hep-G2细胞株的作用研究Effect and Mechanism of Berberine on Human Hepatocellular Carcinoma Cell Line Hep-G2[J]. 中医学, 2018, 07(02): 158-166. https://doi.org/10.12677/TCM.2018.72026</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24153-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Torre, L.A., Bray, F., Siegel, R.L., et al. (2015) Global Cancer Statistics, 2012. Ca A Cancer Journal for Clinicians, 65, 87-108. &lt;br&gt;https://doi.org/10.3322/caac.21262</mixed-citation></ref><ref id="hanspub.24153-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. Ca A Cancer Journal for Clinicians, 66, 115. &lt;br&gt;https://doi.org/10.3322/caac.21338</mixed-citation></ref><ref id="hanspub.24153-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Gong, X.L. and Qin, S.K. (2016) Review and Present Status of Systematic Treatment of Advanced Hepatocellular Carcinomain in 30 Years. Practical Journal of Oncology, 31, 357-397.</mixed-citation></ref><ref id="hanspub.24153-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hano, K. (1959) The Carcinostatic Effects of Some Plant Components and Their Related Compounds. Acta-Unio Internationalis Contra Cancrum, 15, 122.</mixed-citation></ref><ref id="hanspub.24153-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Liu, B., Wang, G., Yang, J., et al. (2011) Berberine Inhibits Human Hepatoma Cell Invasion without Cytotoxicity in Healthy Hepatocytes. PLoS ONE, 6, e21416. &lt;br&gt;https://doi.org/10.1371/journal.pone.0021416</mixed-citation></ref><ref id="hanspub.24153-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ren, K., Zhang, W., Wu, G., et al. (2016) Synergistic Anti-Cancer Effects of Galangin and Berberine through Apoptosis Induction and Proliferation Inhibition in Oesophageal Carcinoma Cells. Biomedicine &amp; Pharmacotherapy, 84, 1748-1759. &lt;br&gt;https://doi.org/10.1016/j.biopha.2016.10.111</mixed-citation></ref><ref id="hanspub.24153-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Q., Wang, J.F. and Ma, J.X. (2013) Radiosensitizing Effect of Berberine on Nude Mice Transplanted with LNCaP Cells of Prostate Cancer. Chinese Journal of Clinicians, 7, 11549-11552.</mixed-citation></ref><ref id="hanspub.24153-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Eo, S.H., Kim, J.H. and Kim, S.J. (2015) Induction of G2/M Arrest by Berberine via Activation of PI3K/Akt and p38 in Human Chondrosarcoma Cell Line. Oncology Research, 22, 147-157.  
&lt;br&gt;https://doi.org/10.3727/096504015X14298122915583</mixed-citation></ref><ref id="hanspub.24153-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Seo, Y.S., Yim, M.J., Kim, B.H., et al. (2015) Berberine-Induced Anticancer Activities in FaDu Head and Neck Squamous Cell Carcinoma Cells. Oncology Reports, 34, 3025-3034. &lt;br&gt;https://doi.org/10.3892/or.2015.4312</mixed-citation></ref><ref id="hanspub.24153-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lei, B.T. and Ma, C.Y. (2014) Research Progress on Anti-Hepatocarcinoma of Berberine. Chinese Archives of Traditional Chinese Medicine, 32, 254-256.</mixed-citation></ref><ref id="hanspub.24153-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">La, X., Zhang, L., Li, Z., et al. (2017) Berberine-Induced Autophagic Cell Death by Elevating GRP78 Levels in Cancer Cells. Oncotarget, 8, 20909-20924. &lt;br&gt;https://doi.org/10.18632/oncotarget.14959</mixed-citation></ref><ref id="hanspub.24153-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mao, B., Zhang, Z. and Wang, G. (2015) BTG2: A Rising Star of Tumor Suppressors (Review). International Journal of Oncology, 46, 459-464. &lt;br&gt;https://doi.org/10.3892/ijo.2014.2765</mixed-citation></ref><ref id="hanspub.24153-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gao, S.S., Yang, X.H. and Wang, M. (2016) Inhibitory Effects of B-Cell Translocation Gene 2 on Skin Cancer Cells via the Wnt/β-Catenin Signaling Pathway. Molecular Medicine Reports, 14, 3464-3468.  
&lt;br&gt;https://doi.org/10.3892/mmr.2016.5596</mixed-citation></ref><ref id="hanspub.24153-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Rouault, J.P., Falette, N., Guéhenneux, F., et al. (1996) Identification of BTG2, an Antiproliferative p53-Dependent Component of the DNA Damage Cellular Response Pathway. Nature Genetics, 14, 482-486.  
&lt;br&gt;https://doi.org/10.1038/ng1296-482</mixed-citation></ref><ref id="hanspub.24153-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.C., Chung, L.C., Chen, Y.J., et al. (2015)Upregulation of B-Cell Translocation Gene 2 by Epigallocatechin-3-Gallate via p38 and ERK Signaling Blocks Cell Proliferation in Human Oral Sduamous Cell Carcinoma Cells. Cancer Letter, 360, 310-318. &lt;br&gt;https://doi.org/10.1016/j.canlet.2015.02.034</mixed-citation></ref><ref id="hanspub.24153-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Micheli, L., Ceccarelli, M., Fariolivecchioli, S., et al. (2015) Control of the Normal and Pathological Development of Neural Stem and Progenitor Cells by the PC3/Tis21/Btg2 and Btg1 Genes. Journal of Cellular Physiology, 230, 2881-2890. &lt;br&gt;https://doi.org/10.1002/jcp.25038</mixed-citation></ref><ref id="hanspub.24153-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Takahashi, F., Chiba, N., Tajima, K., et al. (2011) Breast Tumor Progression Induced by Loss of BTG2 Expression Is Inhibited by Targeted Therapy with the RrbB/HER Inhibitor Lapatinib. Oncogene, 30, 3084-3095.  
&lt;br&gt;https://doi.org/10.1038/onc.2011.24</mixed-citation></ref><ref id="hanspub.24153-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Karve, T.M. and Rosen, E.M. (2012) B-Cell Translocation Gene 2 (BTG2) Stimulates Cellular Antioxidant Defenses through the Antioxidant Transcription Factor NFE2L2 in Human Mammary Epithelial Cells. The Journal of Biological Chemistry, 287, 31503-31514. &lt;br&gt;https://doi.org/10.1074/jbc.M112.367433</mixed-citation></ref><ref id="hanspub.24153-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Takahashi, M., Hayashida, T., Okazak, H., et al. (2014) Loss of B-Cell Translocation Gene 2 Expression in Estrogen Receptor-Positive Breast Cancer Predicts Tamoxifen Resistance. Cancer Science, 105, 675-682.  
&lt;br&gt;https://doi.org/10.1111/cas.12410</mixed-citation></ref><ref id="hanspub.24153-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tsui, K.H., Chung, L.C., Feng, T.H., et al. (2012) Up-Regulation of Prostate-Derived Ets Factor by Luteolin Causes Inhibition of Cell Proliferation and Cell Invasion in Prostate Carcinoma Cells. International Journal of Cancer, 130, 2812-2823. &lt;br&gt;https://doi.org/10.1002/ijc.26284</mixed-citation></ref><ref id="hanspub.24153-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Li, W.Q., Yu, H.Y. and Zhong, N.Z. (2015) miR-27a Suppresses the Clonogenic Growth and Migration of Human Glioblastoma Multiforme Cells by Targeting BTG2. International Journal of Oncology, 46, 1601-1608.  
&lt;br&gt;https://doi.org/10.3892/ijo.2015.2843</mixed-citation></ref><ref id="hanspub.24153-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ye, Y., Xiao, H., Luo, J., et al. (2017) Expression and Clinical Significance of B Cell Translocation Gene 2 in Primary Hepatocellular Carcinoma. Journal of Third Military Medical University, 39, 685-690.</mixed-citation></ref><ref id="hanspub.24153-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Han, P., Wang, Q.L. and Zhang, X. (2016) Expression of TRAP1 in Gastric Cancer Tissue and Its Correlation with Malignant Biology. Asian Pacific Journal of Tropical Medicine, 9, 64-68. &lt;br&gt;https://doi.org/10.1016/j.apjtm.2015.12.014</mixed-citation></ref><ref id="hanspub.24153-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Xia, H., Xiang, S.L., Zeng, Y., et al. (2016) Overexpression of Chk 1/2 Gene G2/M Arrest in MGC803 Cells Induced by Affects Diallyl Disulfide. Chinese Pharmacological Bulletin, No. 2, 199-204.</mixed-citation></ref><ref id="hanspub.24153-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Li, Q.Y., Hao, Y.R., Qin, J., et al. (2016) Effect of BIX-01294 on Cell Proliferation of Liver Cancer. Chinese Journal of Cancer Prevention and Treatment, 23, 487-492.</mixed-citation></ref><ref id="hanspub.24153-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Xu, T., Zhong, L., Gan, L.-G., et al. (2016) Effects of LG268 on Cell Proliferation and Apoptosis of NB4 Cells. International Journal of Medical Sciences, 13, 517-523. &lt;br&gt;https://doi.org/10.7150/ijms.15507</mixed-citation></ref><ref id="hanspub.24153-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Liu, T., Li, W.-M., Wang, W.-P., et al. (2016) Inhibiting CREPT Reduces the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Down-Regulating Cell Cycle Related Protein. American Journal of Translational Research, 8, 2097-2113.</mixed-citation></ref><ref id="hanspub.24153-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, J., Li, L.U., Fang, L.I., et al. (2016) Quercetin Reduces Cyclin D1 Activity and Induces G1 Phase Arrest in HepG2 Cells. Oncology Letters, 12, 516-522. &lt;br&gt;https://doi.org/10.3892/ol.2016.4639</mixed-citation></ref><ref id="hanspub.24153-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z., Chen, C., Wang, G., et al. (2011) Aberrant Expression of the p53-Inducible Antiproliferative Gene BTG2 in Hepatocellular Carcinoma Is Associated with Overexpression of the Cell Cycle-Related Proteins. Cell Biochemistry and Biophysics, 61, 83-91. &lt;br&gt;https://doi.org/10.1007/s12013-011-9164-x</mixed-citation></ref></ref-list></back></article>